BRINP3
BRINP3 (BMP/retinoic acid-inducible neural-specific protein 3) is a member of the BRINP family that restrains neuronal cell proliferation by slowing the cell cycle transition. It is also known as DBCCR1L, DBCCR1L1 and FAM5C. Browse Assay Genie's current range of BRINP3 research reagents below, or read on for the biology behind the target.
BRINP3 inhibits neuronal cell proliferation through negative regulation of the cell cycle transition. In contrast, when overexpressed in pituitary gonadotrope cells it promotes proliferation, migration and invasion, and it is thought to contribute to the development of pituitary tumours. This context-dependent behaviour makes the BRINP3 protein a useful subject for studies of cell cycle control in neural and endocrine tissue.
BRINP3 belongs to the BRINP family and is annotated as both a secreted protein and a mitochondrial protein. The BRINP3 gene produces two transcript variants that encode different isoforms. The protein name reflects its inducibility by bone morphogenetic protein (BMP) and retinoic acid, and its neural-specific character. The gene was previously designated family with sequence similarity 5, member C (FAM5C), and the symbols DBCCR1L and DBCCR1L1 also appear in the literature.
Altered BRINP3 expression has been reported in several diseases. The gene is overexpressed in pituitary tumours but underexpressed in tongue squamous cell carcinomas, ulcerative colitis and peri-implantitis. Polymorphisms that increase its expression have been linked to greater vascular inflammation, and an association with myocardial infarction has been demonstrated. Hypermethylation of the gene may also have value as a biomarker for gastric cancer. Mouse and rat both carry a Brinp3 ortholog.
BRINP3 inhibits neuronal proliferation by negatively regulating the cell cycle transition, making it relevant to studies of neural cell growth.
BRINP3 is overexpressed in pituitary tumours and promotes gonadotrope cell proliferation, migration and invasion when overexpressed.
Reduced expression in tongue squamous cell carcinoma and hypermethylation in gastric cancer point to BRINP3 as a candidate biomarker.
Expression-increasing polymorphisms are linked to vascular inflammation and myocardial infarction, while expression is reduced in ulcerative colitis and peri-implantitis.
BRINP3 inhibits neuronal cell proliferation by negatively regulating the cell cycle transition. When overexpressed in pituitary gonadotrope cells, it instead promotes proliferation, migration and invasion, and it may contribute to pituitary tumour development.
BRINP3 is also called DBCCR1L, DBCCR1L1 and FAM5C (family with sequence similarity 5, member C). Its full name is BMP/retinoic acid-inducible neural-specific protein 3. Two transcript variants encoding different isoforms have been described for the BRINP3 gene.
BRINP3 is overexpressed in pituitary tumours and underexpressed in tongue squamous cell carcinoma, ulcerative colitis and peri-implantitis. It is also associated with myocardial infarction. Mouse and rat each have a Brinp3 ortholog; check the datasheet of any product for its validated reactivity.
Other BRINP family members, cell cycle regulators and pituitary tumour markers with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q76B58; product specifications from Assay Genie datasheets.